当前位置: X-MOL 学术Nat. Rev. Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CGRP-targeted antibodies in difficult-to-treat migraine.
Nature Reviews Neurology ( IF 28.2 ) Pub Date : 2019-12-01 , DOI: 10.1038/s41582-019-0275-0
Tessa de Vries 1 , Antoinette MaassenVanDenBrink 1
Affiliation  

A new study shows that the monoclonal antibody fremanezumab is effective for migraine prophylaxis, even in patients who have failed to respond to multiple preventive treatments. However, not all patients benefit from this treatment, and detailed investigation of non-responders could help to identify additional pharmacological targets and increase the number of responders.

中文翻译:

难以治疗的偏头痛中的 CGRP 靶向抗体。

一项新的研究表明,单克隆抗体fremanezumab 可有效预防偏头痛,即使在对多种预防性治疗无效的患者中也是如此。然而,并非所有患者都能从这种治疗中受益,对无反应者的详细调查可能有助于确定额外的药理学靶点并增加反应者的数量。
更新日期:2019-10-08
down
wechat
bug